CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP)
Health Care · biotechnology · NASDAQ
Corbus Pharmaceuticals is a clinical-stage biotechnology company developing a Nectin-4-targeting antibody-drug conjugate for cancer and a novel CB1 inverse agonist for obesity.
What CORBUS PHARMACEUTICALS HOLDINGS IN does
Corbus Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Its lead candidate, CRB-701, is a Nectin-4-targeting antibody-drug conjugate (ADC) for solid tumors, while its second key asset, CRB-913, is a peripherally restricted CB1 receptor inverse agonist for obesity treatment.
Recent developments
In August 2026, the company received FDA clearance to initiate the TEMPO-1 Phase 3 registrational study of CRB-701 in oropharyngeal cancer and concluded the patient enrollment for the Phase 1b CANYON-1 study of CRB-913. The company also strengthened its executive team with the appointments of a new Chief Medical Officer and Chief Business Officer.
From CORBUS PHARMACEUTICALS HOLDINGS IN's filing of 2026-08-06.
Themes: oncology, obesity, antibody-drug conjugates (ADCs), clinical-stage biopharma
Fundamentals
- Price$5.27 as of 2026-10-08 close
- Market cap$102M as of 2026-08-04 (share count; price 2026-10-08)
- 1-year return-60.7% 2025-10-08 close $13.42 → 2026-10-08 close $5.27
- P/En/a negative earnings
- ROE-53.2% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.08 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CRBP compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CORBUS PHARMACEUTICALS HOLDINGS IN looks technically
CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) is trading 40.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 48, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 21, in oversold territory (below 30). It just made a new 20-day low, breaking below its recent trading range. It is 2.5% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 40.9% below its 200-day average, the long-term trend line — a long-term downtrend | -40.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.86 | $8.86 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.91 | $8.91 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 7.98. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 1 trading day ago — a "death cross", a bearish long-term signal | 1 session |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 48, with sellers in control | 48.2 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 21, in oversold territory (below 30) | 21.0 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($5.14 to $7.98) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 4.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 23 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $20.56 | $20.56 |
|---|---|---|
| From the 52-week high | it is 74.4% below its 52-week high (its highest price of the past year) | -74.4% |
| Above the 52-week low | it is 2.5% above its 52-week low (its lowest price of the past year) | +2.5% |
| Below the 52-week high | it is 74.4% below its highest point of the past year | 74.4% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $323.40 (set on 2016-10-10) | $323.40 |
| Given back of the 52-week move | over the past year its closes ranged ($5.27 to $19.36), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.98 to $14.43. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 98.4% below its all-time high | -98.4% |
| Nearest price level | it is trading 36.3% below a resistance level at $7.18 — a price it turned at three times since 2025-03-11, most recently on 2026-06-02. Since 2024-10-08 it has 0 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +36.3% |
| All-time low | its lowest closing price on record is $2.11 (set on 2023-03-10) | $2.11 |
| Above the all-time low | it is 149.8% above its all-time low | +149.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 75% of it) | 75th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5263 between its high and its low — about 10.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5263 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.23 and $8.59 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.23 – $6.91 – $8.59 |
| Typical daily range (% of price) | its price moves about 10.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.0% |
| Stretch from the 200-day average | it is trading 6.9 daily ranges below its 200-day average price (40.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.18× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Gap filled | a 3.9% gap up opened on 2026-10-02 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 6 sessions in a row, a -22.73% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 6 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 51.3 percentage points (the stock lost 50.3% while the market gained 1.0%) | -51.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 48.6 percentage points (the stock lost 44.8% while the market gained 3.8%) | -48.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 65.5 percentage points (the stock lost 48.0% while the market gained 17.5%) | -65.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 75.7 percentage points (the stock lost 60.7% while the market gained 15.0%) | -75.7% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 46% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -45.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 39% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $8.62 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | -38.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 36% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $8.29 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -36.4% |
Price levels it has turned at before
CRBP last closed at $5.27 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 14 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.18 | Resistance | 36.3% above the last close | turned there three times · 2025-03-11 to 2026-06-02 |
| $7.67 | Resistance | 45.6% above the last close | turned there twice · 2026-01-05 to 2026-01-13 |
| $7.97 | Resistance | 51.3% above the last close | turned there twice · 2025-12-19 to 2026-09-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $7.98.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $7.98.
This reading has stood for 7 trading days, since 2026-09-30.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Oversold (14-day RSI below 30) · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$34.03 range $17.25 – $48.00; median $34.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CRBP
- Consensus EPS estimate-$1.21 next reporting period, as of 2026-10-08
- Estimate change, 30 days$0.00 from -$1.21, on 2026-09-03, 35-day window
- Readings revised upward0% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has a history of operating losses and its business remains highly speculative; it requires substantial additional capital to fund clinical development.","Clinical trials may fail to demonstrate safety or efficacy, or face regulatory delays or denials."]
What changed in the latest 10-Q
AI-assisted comparison of CRBP's 10-Q filed 2026-08-06 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
- Added:
- The newer filing (2026-08-06) added disclosure that on June 12, 2026, Yong Ben, M.D., a board member, adopted a Rule 10b5-1 plan for the sale of up to 7,583 shares, with sales beginning September 14, 2026 and termination on May 30, 2027.
- The newer filing (2026-08-06) added exhibit 10.1 (Amendment to the 2024 Equity Compensation Plan, incorporated by reference to Form 8-K filed May 14, 2026).
- The newer filing (2026-08-06) added exhibit 10.2 (Employment Agreement with Nishant Saxena, incorporated by reference to Form 8-K filed May 21, 2026).
- The newer filing (2026-08-06) added exhibit 10.3 (2026 Inducement Award Plan, incorporated by reference to Form S-8 filed June 17, 2026).
- The newer filing (2026-08-06) added exhibit 10.4 (Form of Inducement Restricted Stock Unit Award Agreement, incorporated by reference to Form S-8 filed June 17, 2026).
- The newer filing (2026-08-06) added exhibit 10.5 (Form of Inducement Stock Option Award Agreement, incorporated by reference to Form S-8 filed June 17, 2026).
- The newer filing (2026-08-06) added exhibit 10.6 (Lease Amendment No. 3, dated April 1, 2026).
- The newer filing (2026-08-06) added exhibit 10.7 (Employment Agreement with Leonardo Viana Nicacio, MD, dated July 2, 2026, incorporated by reference to Form 8-K filed July 6, 2026).
- Removed:
- The newer filing (2026-08-06) removed the disclosure that on March 11, 2026, Yuval Cohen, Ph.D., CEO and board member, adopted a Rule 10b5-1 plan for the sale of up to 270,075 shares.
- The newer filing (2026-08-06) removed the disclosure that on March 11, 2026, Sean Moran, CFO, adopted a Rule 10b5-1 plan for the sale of up to 124,852 shares.
- The newer filing (2026-08-06) removed the disclosure that on March 11, 2026, Anne Altmeyer, Ph.D., a board member, adopted a Rule 10b5-1 plan for the sale of up to 4,800 shares.
- The newer filing (2026-08-06) removed the disclosure that on March 11, 2026, John Jenkins, M.D., a board member, adopted a Rule 10b5-1 plan for the sale of up to 7,453 shares.
- The newer filing (2026-08-06) removed the disclosure that on March 11, 2026, Winston Kung, a board member, adopted a Rule 10b5-1 plan for the sale of up to 4,800 shares.
- The newer filing (2026-08-06) removed exhibit 10.1 (Form of Sixth Amended and Restated Employment Agreement with Yuval Cohen).
- The newer filing (2026-08-06) removed exhibit 10.2 (Form of Seventh Amended and Restated Employment Agreement with Sean Moran).
- Reworded:
- The newer filing (2026-08-06) updated the closing statement about no other directors or officers adopting/modifying/terminating trading arrangements from "during the first quarter of 2026" (2026-05-12 filing) to "during the second quarter of 2026".
- The cover page description in exhibit item 104 changed from "quarterly period ended March 31, 2026" (2026-05-12 filing) to "quarterly period ended June 30, 2026" (2026-08-06 filing).
- The signature date changed from May 12, 2026 (2026-05-12 filing) to August 6, 2026 (2026-08-06 filing).
- Notes:
- The provided section labeled 'Risk Factors' in both filings contains only the statement that there have been no material changes to the risk factors in the 2025 Annual Report, followed by other Items 2-6. Changes noted are primarily in the 'Director and Officer Trading Arrangements' and exhibit index portions of the extracted text.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 3 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 1 sell ($15683) — 1 selling insider
- Last 90 days · read to 2026-10-041 buy ($25036) · 3 sells ($308050) — 1 buying, 3 selling insiders
- Last 180 days · read to 2026-10-043 buys ($126255) · 6 sells ($381156) — 1 buying, 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-14. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CRBP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CRBP as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,154,788
- Reported value $20,211,912
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CRBP's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CRBP had 2,759,255 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CRBP had 14.3% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.54 days to cover at the same settlement.
- Reported short interest (shares) 2,759,255
- Short interest (% of shares outstanding) 14.3%
- Prior settlement (shares) 2,245,998
- Reported change 22.85%
- Days to cover (reported) 1.54
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Seagen (Pfizer)
- AstraZeneca (AZN)
- Bristol Myers Squibb (BMY)
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CRBP vs…
CORBUS PHARMACEUTICALS HOLDINGS IN is found in…
Frequently asked questions
What does CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) do?
Corbus Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Its lead candidate, CRB-701, is a Nectin-4-targeting antibody-drug conjugate (ADC) for solid tumors, while its second key asset, CRB-913, is a peripherally restricted CB1 receptor inverse agonist for obesity treatment.
What sector is CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) in?
CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CORBUS PHARMACEUTICALS HOLDINGS IN's (CRBP) competitors?
Notable peers of CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) include Seagen (Pfizer), AstraZeneca, Bristol Myers Squibb, Novo Nordisk and Eli Lilly. This peer set is informational only — not financial advice.
Is CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) overbought or oversold right now?
CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) is currently in oversold territory (its 14-day RSI is 21, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CRBP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.